Biological Evaluation of Oxindole Derivative As a Novel Anticancer Agent Against Human Kidney Carcinoma Cells

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2020 Sep 4

PMID 32878322

Citations 1

Authors

Prasanta Dey

Amit Kundu

Sang Hoon Han

Kyeong-Seok Kim

Jae Hyeon Park

Sungpil Yoon

In Su Kim

Hyung Sik Kim

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma has emerged as one of the leading causes of cancer-related deaths in the USA. Here, we examined the anticancer profile of oxindole derivatives (SH-859) in human renal cancer cells. Targeting 786-O cells by SH-859 inhibited cell growth and affected the protein kinase B/mechanistic target of rapamycin 1 pathway, which in turn downregulated the expression of glycolytic enzymes, including lactate dehydrogenase A and glucose transporter-1, as well as other signaling proteins. Treatment with SH-859 altered glycolysis, mitochondrial function, and levels of adenosine triphosphate and cellular metabolites. Flow cytometry revealed the induction of apoptosis and G0/G1 cell cycle arrest in renal cancer cells following SH-859 treatment. Induction of autophagy was also confirmed after SH-859 treatment by acridine orange and monodansylcadaverine staining, immunocytochemistry, and Western blot analyses. Finally, SH-859 also inhibited the tumor development in a xenograft model. Thus, SH-859 can serve as a potential molecule for the treatment of human renal carcinoma.

Citing Articles

Design, Synthesis, and Evaluation of the COX-2 Inhibitory Activities of New 1,3-Dihydro--indolin-2-one Derivatives.

Pan T, He M, Deng L, Li J, Fan Y, Hao X Molecules. 2023; 28(12).

PMID: 37375225 PMC: 10305287. DOI: 10.3390/molecules28124668.

References

Iansante V, Choy P, Fung S, Liu Y, Chai J, Dyson J . PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun. 2015; 6:7882. PMC: 4918319. DOI: 10.1038/ncomms8882. View

Xing T, He H . Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res. 2016; 28(1):80-91. PMC: 4779762. DOI: 10.3978/j.issn.1000-9604.2016.02.09. View

Xiang C, Cui S, Ke Y . MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR. J Huazhong Univ Sci Technolog Med Sci. 2016; 36(2):186-192. DOI: 10.1007/s11596-016-1564-0. View

Moretti L, Cha Y, Niermann K, Lu B . Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress?. Cell Cycle. 2007; 6(7):793-8. DOI: 10.4161/cc.6.7.4036. View

Garber K . Energy deregulation: licensing tumors to grow. Science. 2006; 312(5777):1158-9. DOI: 10.1126/science.312.5777.1158. View

Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo R, Kolenko V . Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther. 2018; 17(7):1355-1364. PMC: 6034114. DOI: 10.1158/1535-7163.MCT-17-1299. View

Bort A, Quesada S, Ramos-Torres A, Gargantilla M, Priego E, Raynal S . Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation. Sci Rep. 2018; 8(1):4370. PMC: 5847527. DOI: 10.1038/s41598-018-22690-2. View

Romagnoli R, Baraldi P, Prencipe F, Oliva P, Baraldi S, Salvador M . Design, synthesis and biological evaluation of 3-substituted-2-oxindole hybrid derivatives as novel anticancer agents. Eur J Med Chem. 2017; 134:258-270. DOI: 10.1016/j.ejmech.2017.03.089. View

Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L . Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol. 2006; 8(10):1124-32. DOI: 10.1038/ncb1482. View

10.

Robb V, Karbowniczek M, Klein-Szanto A, Henske E . Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol. 2006; 177(1):346-52. DOI: 10.1016/j.juro.2006.08.076. View

11.

Dutcher J . Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol. 2013; 5(6):338-53. PMC: 3825112. DOI: 10.1177/1756287213505672. View

12.

Ferri K, Kroemer G . Organelle-specific initiation of cell death pathways. Nat Cell Biol. 2001; 3(11):E255-63. DOI: 10.1038/ncb1101-e255. View

13.

DArcy M . Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019; 43(6):582-592. DOI: 10.1002/cbin.11137. View

14.

Tian T, Li X, Zhang J . mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int J Mol Sci. 2019; 20(3). PMC: 6387042. DOI: 10.3390/ijms20030755. View

15.

Cao Q, Ruan H, Wang K, Song Z, Bao L, Xu T . Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma. Int J Oncol. 2018; 53(1):137-147. PMC: 5958875. DOI: 10.3892/ijo.2018.4384. View

16.

Zhang G, Wu Y, Zhang J, Fang Z, Liu Z, Xu Z . Nomograms for predicting long-term overall survival and disease-specific survival of patients with clear cell renal cell carcinoma. Onco Targets Ther. 2018; 11:5535-5544. PMC: 6134959. DOI: 10.2147/OTT.S171881. View

17.

Cho D, Jo Y, Hwang J, Lee Y, Roh S, Kim J . Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett. 2008; 274(1):95-100. DOI: 10.1016/j.canlet.2008.09.004. View

18.

Sathianathen N, Krishna S, Anderson J, Weight C, Gupta S, Konety B . The current status of immunobased therapies for metastatic renal-cell carcinoma. Immunotargets Ther. 2017; 6:83-93. PMC: 5723125. DOI: 10.2147/ITT.S134850. View

19.

Chu B, Wang J, Wang Y, Yang G . Knockdown of PKM2 induces apoptosis and autophagy in human A549 alveolar adenocarcinoma cells. Mol Med Rep. 2015; 12(3):4358-4363. DOI: 10.3892/mmr.2015.3943. View

20.

Kastan M, Bartek J . Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015):316-23. DOI: 10.1038/nature03097. View